Hematological Malignancies Market size is estimated to reach $106.4 billion by 2027, growing at a CAGR of 10.2% during the forecast period 2022-2027. The word hematological is related to blood whereas malignancies represent cancerous growth. Therefore, hematological malignancies can be delineated as an abnormal growth of cancer cells in blood-forming tissues like bone marrow. Hematological malignancies fall under mainly three types, namely multiple myeloma, lymphoma, and leukemia. This tumor attacks blood cells and lymph nodes. Consequently, with the hampered functioning of red blood and white blood cells body’s ability to fight infections diminishes quickly and it starts to perish.
Competitive Landscape:
The top 5 players in the Hematological Malignancies industry are –
1. Pfizer Inc.
2. F. Hoffmann-LA Roche
3. AstraZeneca
4. AbbVie Company
5. GlaxoSmithKline Pharmaceutical
Interested in knowing more relevant information? Click here:
https://www.industryarc.com/pdfdownload.php?id=15722
Segmental Analysis:
1. Hematological Malignancies Market based on the disease type can be further segmented into multiple myeloma, lymphoma, leukemia (=lymphocytic, myeloid), and others. The lymphoma segment held the largest share in 2021. According to a study, diffused large B-cell lymphoma dominates other types of hematological malignancy types due to its mutation-prone nature.
2. Hematological Malignancies Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 34% of the overall market in 2021.
3. Hematological Malignancies Market based on treatment type can be further segmented into Chemotherapy, Immunotherapy, Radiotherapy, and Stem Cell Transplantation. The chemotherapy segment held the largest share in 2021. Around 650,000 cancer patients each year within the US received chemotherapy.
|
Report Coverage |
|
|
Report Attributes |
Details |
|
By Disease Type |
Multiple Myeloma, Lymphoma, Leukemia
|
|
By Treatment Type |
Chemotherapy, Immunotherapy, Radiotherapy, and Stem Cell Transplantation.
|
|
By Treatment Provider |
Hospitals and Diagnostic centers.
|
|
By Geography |
North America, Europe, Asia-Pacific, South America and Rest of World |
Get more detailed information about these segments in the report. Buy it here:
https://www.industryarc.com/reports/request-quote?id=15722
Market Drivers and Challenges:
1. Shooting up nuclear power plants and smoking trends is anticipated to boost product demand : Excessive smoking habits and radiations exposure are the foremost factors behind the prevalence of hematological malignancies. The trend of smoking is rising among adults, especially youngsters.
2. The growing geriatric population and research activities are expected to Boost Product Demand : It has been noted that the prevalence of blood cancer is congruent with elevating old-age population. According to a study, every year around 1.24 million cases of leukemia and lymphoma occurs around the globe.
3. The high cost of cancer treatments is anticipated to hamper market growth : Not everyone can afford the cost of cancer treatment. They can cost a person an arm and leg. As of 2021 around 9.2% of the world, the population is living in deprived conditions.
Why IndustryARC?
IndustryARC is one of the leading market research and consulting firms in the world. It produces over 500 unique market reports annually. Get detailed report on preferred market as per your specific requirements and our research experts would customize the report for you.
Email: venkat@industryarc.com
USA: (+1) 614-588-8538, (+1) 815-656-4596
Similar Reports:
A. Cancer Diagnostics Market
https://www.industryarc.com/Report/15739/cancer-diagnostics-market.html
B. Large Cell Lymphoma Market
https://www.industryarc.com/Report/15733/large-cell-lymphoma-market.html
Media Contact
Company Name: IndustryARC
Contact Person: Mr. Venkat Reddy
Email: Send Email
Phone: (+1) 970-236-3677
Address:Madhapur
City: Hyderabad
Country: India
Website: https://www.industryarc.com/Report/15722/hematological-malignancies-market.html
